What does 6630507 mean?
6,630,507, granted in 2003 to the U.S. Department of Health and Human Services and covering the potential use of non-psychoactive cannabinoids to protect the brain from damage or degeneration caused by certain diseases, such as cirrhosis.
Who holds the patent for CBD?
The CBD Patent was originally filed in 1999 and awarded a patent in 2003 – almost 20 years ago. The United States federal government holds the patent on non-psychoactive cannabinoids — including CBD, as a treatment for specific illnesses.
What is the patent number for Ebola?
CA 2741523
Patent 2741523 Summary
| (12) Patent: | (11) CA 2741523 |
|---|---|
| (54) English Title: | HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF |
| (54) French Title: | ESPECE DE VIRUS EBOLA HUMAIN ET COMPOSITIONS ET PROCEDES ASSOCIES |
| Status: | Granted |
What herb does the government have a patent on?
marijuana
U.S. Patent 6,630,507. The U.S. government holds Patent No. 6,630,507. This patent is in relation to marijuana and its use for treating certain medical conditions.
Is Zika virus patented?
The Rockefeller Foundation has also addressed claims that it patented the virus, confirming this is not true. It explained that a foundation-supported centre first discovered Zika in Entebbe, Uganda in 1947, and later gave a sample to ATCC.
Who owns Ebola?
It was developed by the Public Health Agency of Canada, with development subsequently taken over by Merck Inc. In October 2014, the Wellcome Trust, who was also one of the biggest UK founders, announced the start of multiple trials in healthy volunteers in Europe, Gabon, Kenya, and the US.
What is US patent 5676977?
US 5676977 A – Method of curing AIDS with tetrasilver tetroxide molecular crystal devices | The Lens.
WHO made the Ebola cure?
It was developed by NIAID in collaboration with Okairos, now a division of GlaxoSmithKline. For the trial designated VRC 20, 20 volunteers were recruited by the NIAID in Bethesda, Maryland, while three dose-specific groups of 20 volunteers each were recruited for trial EBL01 by University of Oxford, UK.